Sameh Salma, Abdollah Maha R A, Elissawy Ahmed M, Al-Sayed Eman, Labib Rola M, Ye Lan, Chang Fang-Rong, Singab Abdel Nasser B
Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, 11566, Egypt.
Department of Pharmacology, Faculty of Pharmacy, The British University in Egypt, El Sherouk City, Egypt.
Sci Rep. 2025 May 25;15(1):18166. doi: 10.1038/s41598-025-02717-1.
Herbal nutraceuticals could be employed as alternative or complementary routes for alleviating cancer. Corchorus olitorius (Malvaceae) was employed traditionally in the management of tumors. The study aimed to investigate the antiproliferative activity of C. olitorius leaves. In vitro cytotoxic and anti-angiogenic activities of C. olitorius were estimated. The bioactive fraction was subjected to in vivo study on BALB/ c female mice using Ehrlich Ascites Carcinoma model. UPLC-ESI-MS/MS analysis was done to determine the phytometabolites followed by in silico studies on the major identified compounds. The bioactive fraction possessed potent in vitro activity against A549 cells with IC = 7.8 µg/mL and exhibited strong anti-angiogenic activity. The in vivo study revealed the safety of the fraction and confirmed its anticancer activity. The tumor volume in the fraction treated group was reduced by 33.7% compared to the control group. UPLC-ESI-MS/MS analysis led to the identification of 25 compounds belonging to different chemical classes. The in silico pharmacodynamic profile revealed that the compounds exhibited agreeable binding affinities toward EGFR, CDK2 and VEGF-A comparable to the standard drugs. C. olitorius is a promising herbal nutraceutical from which effective chemopreventive and anticancer formulations can be developed following further in depth studies.
草药营养补充剂可作为缓解癌症的替代或补充途径。传统上,黄麻(锦葵科)被用于治疗肿瘤。本研究旨在调查黄麻叶的抗增殖活性。评估了黄麻的体外细胞毒性和抗血管生成活性。使用艾氏腹水癌模型对BALB/c雌性小鼠进行了生物活性组分的体内研究。进行超高效液相色谱-电喷雾串联质谱(UPLC-ESI-MS/MS)分析以确定植物代谢产物,随后对主要鉴定出的化合物进行计算机模拟研究。该生物活性组分对A549细胞具有强大的体外活性,IC50 = 7.8 μg/mL,并表现出很强的抗血管生成活性。体内研究揭示了该组分的安全性并证实了其抗癌活性。与对照组相比,组分治疗组的肿瘤体积减少了33.7%。UPLC-ESI-MS/MS分析鉴定出25种属于不同化学类别的化合物。计算机模拟药效学分析表明,这些化合物对表皮生长因子受体(EGFR)、细胞周期蛋白依赖性激酶2(CDK2)和血管内皮生长因子-A(VEGF-A)表现出与标准药物相当的适宜结合亲和力。黄麻是一种很有前景的草药营养补充剂,经过进一步深入研究后可开发出有效的化学预防和抗癌制剂。